NCT05041166View on ClinicalTrials.gov

A Study of [13C]Pyruvate as an Imaging Agent for Magnetic Resonance Imaging in Healthy Volunteers

PHASE1Enrolling by invitationINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

September 1, 2021

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2026

Conditions
Healthy Volunteers
Interventions
DRUG

Hyperpolarized [13C] Pyruvate

Will be injected at a dosage of 0.43 ± 0.05 mL/kg body weight

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York

All Listed Sponsors
collaborator

Sunnybrook Health Sciences Centre

OTHER

lead

Memorial Sloan Kettering Cancer Center

OTHER